A
systematic review was performed to reassess the clinical safety and effectiveness
of F-18 FLT PET used on patients with lung cancer. For the assessment, the
technology was defined in accordance with the notification (do-225) stipulated
by the Health Insurance Review and Assessment Service and search strategy used
in the previous new health technology assessment was followed.
For
systematic review, five Korean and three foreign databases were searched based
on the key question. Two reviewers independently screened and selected the
articles according to the selection and exclusion criteria. Risk of bias
assessment was performed independently by two reviewers using QUADAS-2 until an
agreement was reached. Data were extracted independently by two reviewers using
pre-determined format. If there was a disagreement between the reviewers, such
cases were discussed with a third party to reach an agreement. Meta-analysis
was performed when quantitative analysis was possible and qualitative review was
applied when otherwise.
A
total of 21 articles related to F-18 FLT PET or PET/CT were identified through
the systematic review and these articles were used for the safety and effectiveness
assessment.
One
article reported that there was no incidence of adverse events associated with F-18
FLT PET/CT. Accordingly, it was determined that there are no safety concerns.
The effectiveness
of this test was assessed by the diagnostic accuracy for metastasis, accuracy
of disease staging, cell proliferation (correlation with comparator test),
treatment response, and impact on health outcomes.
With
respect to diagnostic accuracy for metastasis and accuracy of disease staging,
three articles compared F-18 FLT PET and F-18 FDG PET and all three articles
reported that F-18 FLT PET showed higher accuracies. However, the study by Yamamoto
et al. (2008) reported that there was no statistical significance.
With
respect to cell proliferation assessment, there was a total of seven articles
that compared the correlation between the index test and comparator tests (Ki-67
in six articles and cyclin D1 in one article). The results showed that F-18 FLT
PET (or PET/CT) has a moderately significant correlation with comparator tests
in the cell proliferation assessment (r=0.555, 95% CI 0.048, 0647).
Treatment
response was assessed by progression-free survival (PFS), overall survival
(OS), and standardized uptake value (SUV).
A
total of seven articles reported on PFS. Five out of six studies that compared
PFS between F-18 FLT PET (or PET/CT) response and non-response groups after
chemotherapy reported that there were significant differences between the two
groups. In particular, early outcomes (first week) were found to be significant
predictors of PFS. However, one study (Bhoil et al., 2014) reported no significant
difference, presenting conflicting results on prediction of PFS. One study (Everitt
et al., 2017) that compared PFS between F-18 FLT PET (or PET/CT) response and
non-response groups after chemoradiotherapy reported that the non-response
group showed better PFS, but the difference was not statistically significant.
A
total of eight articles reported on OS. All five studies that compared OS
between F-18 FLT PET (or PET/CT) response and non-response groups after
chemotherapy reported no significant differences between the two groups, and
thus, predicting OS with F-18 FLT PET (or PET/CT) was found to be difficult.
Two studies that compared OS between F-18 FLT PET (or PET/CT) response and
non-response groups after chemoradiotherapy also reported no significant
differences between the two groups. One study (Scheffler et al., 2013) compared
OS between F-18 FLT PET (or PET/CT) response and non-response groups before
treatment and reported that F-18 FLT PET and F-18 FDG PET non-response group
had statistically significantly better OS than the response group.
Eight
studies reported on SUV of F-18 FLT PET (or PET/CT). Three studies that
reported on SUV of F-18 FLT PET/CT at before and after treatment reported that
SUV of F-18 FLT PET/CT decreased after the treatment.
There
were no studies that reported any impact on treatment outcomes, such as changes
in patient care by performing this test.
The F-18
FLT PET subcommittee proposed the following based on the currently available
assessment results. While F-18 FLT PET was found to have no safety concerns,
its effectiveness was confirmed only in some results. Evidence currently
available has confirmed clear clinical effectiveness for diagnostic accuracy
(metastasis and disease staging) and cell proliferation assessment, whereas,
evidence of its effectiveness for prognosis/prediction through treatment
response assessment has not been found. However, the subcommittee determined
that such results did not demonstrate much inferior effectiveness than F-18 FDG
PET, which is universally used today, and that the effectiveness of treatment
response assessment was at a similar level. Accordingly, it was determined that
F-18 FLT PET is a safe and effective test method for determining treatment
effect and predicting prognosis after chemotherapy or radiotherapy in patients
in lung cancer.
The
Health Technology Reassessment Committee reviewed and determined that the
findings of the subcommittee on F-18 FLT PET are valid (October 11, 2019).